



2023 Medicare Part D Step Therapy Requirements

Effective: December 1st, 2023

METOCLOPRAMIDE ODT

MEDICATION(S) SUBJECT TO STEP THERAPY

METOCLOPRAMIDE HCL ODT

CRITERIA

PRIOR USE OF METOCLOPRAMIDE TABLETS OR SOLUTION WITHIN THE PREVIOUS 12 MONTHS.

MUPIROCIN

MEDICATION(S) SUBJECT TO STEP THERAPY

MUPIROCIN 2% CREAM

CRITERIA

PRIOR USE OF MUPIROCIN OINTMENT WITHIN THE PREVIOUS 12 MONTHS.

RYTARY

MEDICATION(S) SUBJECT TO STEP THERAPY

RYTARY

CRITERIA

PRIOR USE OF CARBIDOPA-LEVODOPA IMMEDIATE RELEASE OR EXTENDED RELEASE WITHIN THE PREVIOUS 12 MONTHS.

TAZAROTENE

MEDICATION(S) SUBJECT TO STEP THERAPY

TAZAROTENE 0.05% GEL, TAZAROTENE 0.1% GEL, TAZORAC 0.05% CREAM

CRITERIA

PRIOR USE OF TAZAROTENE 0.1% CREAM WITHIN THE PREVIOUS 12 MONTHS.